Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851271 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL15754346 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8718435 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8375908 | 0.88 | AKR1B1 (0.32) | LMNAL3MBTL1AKR1B1 | |
| SCHEMBL2848010 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8486 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2316300 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL3507128 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL3507130 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL1921547 | 0.79 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111484565-A | Sweet wormwood polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | 复旦大学 | 2020-08-04 | — | — | CN | claimed |
| US-12605431-B2 | Composition for treating or preventing myopathy, obesity or diabetes | NB SCIENCE CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| WO-2024151612-A1 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES | DERMATA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240099962-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | DERMATA THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240058428-A1 | COMPOSITION FOR TREATING OR PREVENTING MYOPATHY, OBESITY OR DIABETES | NB SCIENCE CO., LTD. (KR) | 2024-02-22 | — | — | US | disclosed |
| EP-4267163-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | Dermata Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4261283-A1 | COMPOSITION FOR TREATING OR PREVENTING MYOPATHY, OBESITY OR DIABETES | Nuon Bio Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125678-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | DERMATA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220175660-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | DERMATA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-111484565-B | Sweet wormwood polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | 复旦大学 | 2022-06-07 | — | — | CN | disclosed |
| US-20040180854-A1 | Oligosaccharide aldonic acids and their topical use | YU RUEY J (US) | 2004-09-16 | — | — | US | disclosed |
| US-6740327-B2 | USE FOR COSMETIC AND DERMATOLOGICAL INDICATIONS, REDUCING AND SOOTHING MUCOSA AND SKIN ERYTHEMA, INFLAMMATION OR REACTION CAUSED BY INTERNAL OR EXTERNAL FACTORS, WOUND HEALING, ETC. | YU RUEY J (US) | 2004-05-25 | — | — | US | disclosed |
| CN-1460714-A | Cell activation and adverse-resisting gene inductor and its prepartion method | WU YING (CN) | 2003-12-10 | — | — | CN | disclosed |
| EP-1227820-A2 | OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE | Yu, Ruey J., Dr. (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6403090-B1 | Peptides which mimic candida carbohydrate epitopes and their use in a vaccine | THE RESEARCH AND DEVELOPMENT INSTITUTE INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020028227-A1 | Oligosaccharide aldonic acids and their topical use | YU RUEY J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6335023-B1 | VEHICLES AND OLIGOSACCHARIDE ALDONIC ACIDS | YU RUEY J (US) | 2002-01-01 | — | — | US | disclosed |
| WO-2001001932-A2 | OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE | YU RUEY J (US) | 2001-01-11 | — | — | WO | disclosed |
| US-4184917-A | VIRICIDES, BIOSYNTHESIS WITH GALACTOSIDASE | SANDOZ LTD. (CH) | 1980-01-22 | — | — | US | disclosed |
| US-4061538-A | GALACTOSE OXIDASE | SANDOZ LTD. (CH) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028227-A1 | Oligosaccharide aldonic acids and their topical use | GLA, ALDOA, MAN2A1 | LMNA 500/4885L3MBTL1 4233/4885TDP1 1310/4885 |
| US-12605431-B2 | Composition for treating or preventing myopathy, obesity or diabetes | MTPN, ADAMTS1, ADAMTS13 | LMNA 588/4885L3MBTL1 111/4885TDP1 215/4885 |
| US-20040180854-A1 | Oligosaccharide aldonic acids and their topical use | GLA, ALDOA, MAN2A1 | LMNA 500/4885L3MBTL1 4233/4885TDP1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.